Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 64Neoplasms 37Colorectal Neoplasms 35Neoplasm Metastasis 32Breast Neoplasms 31Ovarian Neoplasms 28Prostatic Neoplasms 27Pancreatic Neoplasms 27Recurrence 26Multiple Myeloma 25Melanoma 24Squamous Cell Carcinoma of Head and Neck 23Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lung Neoplasms 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 15Stomach Neoplasms 14Leukemia, Myeloid, Acute 14Colonic Neoplasms 14Burkitt Lymphoma 14Carcinoma, Renal Cell 13Small Cell Lung Carcinoma 12Glioma 12Uterine Cervical Neoplasms 11Sarcoma 11Lymphoma 11Head and Neck Neoplasms 11

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × 30 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡